Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CASIRIVIMAB\IMDEVIMAB Cause Intentional product use issue? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Intentional product use issue have been filed in association with CASIRIVIMAB\IMDEVIMAB. This represents 0.3% of all adverse event reports for CASIRIVIMAB\IMDEVIMAB.

13
Reports of Intentional product use issue with CASIRIVIMAB\IMDEVIMAB
0.3%
of all CASIRIVIMAB\IMDEVIMAB reports
0
Deaths
8
Hospitalizations

How Dangerous Is Intentional product use issue From CASIRIVIMAB\IMDEVIMAB?

Of the 13 reports, 8 (61.5%) required hospitalization.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CASIRIVIMAB\IMDEVIMAB. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does CASIRIVIMAB\IMDEVIMAB Cause?

Infusion related reaction (875) Dyspnoea (687) Nausea (416) Oxygen saturation decreased (390) Dizziness (357) Pyrexia (306) Chest discomfort (294) Chills (265) Flushing (238) Cough (235)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which CASIRIVIMAB\IMDEVIMAB Alternatives Have Lower Intentional product use issue Risk?

CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN CASIRIVIMAB\IMDEVIMAB vs CATEQUENTINIB CASIRIVIMAB\IMDEVIMAB vs CC-4047 CASIRIVIMAB\IMDEVIMAB vs CEDAZURIDINE\DECITABINE CASIRIVIMAB\IMDEVIMAB vs CEDIRANIB

Related Pages

CASIRIVIMAB\IMDEVIMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue CASIRIVIMAB\IMDEVIMAB Demographics